AdAlta Limited Report issue

For profit Phase 1
Founded: Melbourne Australia (2007)

Organization Overview

First Clinical Trial
2020
NCT04415671
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

AdAlta Limited

Active Ingredients

Drugs in Phase 1 Trials (1)

ad-214 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases (Phase 1)

Lung Diseases, Interstitial (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1